Pharmacogenetic biomarkers of response in Crohn’s disease

Teresa Linares-Pineda, Maria Luisa Canadas Garre, Antonio Sanchez-Pozo, Miguel Angel Calleja Hernandez

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)
463 Downloads (Pure)


Crohn’s disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and
be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a
combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others.
The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment,
including corticosteroids, immunomodulators and biologic therapy (infliximab and adalimumab), which have shown differences in
response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences
in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response
to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F,
TNF and TNFR genes. In this review, we will gather the information on influence of gene polymorphisms investigated to date on
response to biological drugs in CD patients.
Original languageEnglish
Pages (from-to)1-13
JournalThe pharmacogenomics journal
Early online date20 Jun 2017
Publication statusEarly online date - 20 Jun 2017


Dive into the research topics of 'Pharmacogenetic biomarkers of response in Crohn’s disease'. Together they form a unique fingerprint.

Cite this